ESTRO 2022 - Abstract Book

S621

Abstract book

ESTRO 2022

Abstract Text Introduction: Mentorship programs are designed to help foster younger generations into their desired fields by offering a helping hand from more experienced, versed senior colleagues. The following presentation will describe this mentee’s experience in ESTRO’s first mentorship program. Methods: After selection into the ESTRO Mentorship Pilot Program, a selection of mentors and mentees was held at the ESTRO 2021 Congress. After being matched with a preferred mentor, virtual meetings were scheduled at regular intervals, based on our preferences. Sessions were to revolve around personal objectives in the workplace, professional goals, and how to best bring them to fruition. Results: Meetings were held at regular 6 – 8 week intervals, centered around my career priorities and goals. A contract- style agreement was proposed between the mentee-mentor and a yearly plan for career advancement was formulated. Valuable input was given on the appropriate radiotherapy societies I might adhere to, suitable journals to publish my work and recommendation letters were issued for these applications. Discussion : Looking back, upon objective review the routine meetings gave a sense of responsibility to report upon progress and to finish transforming ideas into tangible projects. The revision of career goals made rethinking of yearly plans a full endeavor with time-constrained goals. From a more personal, subjective analysis these meetings uplifted my view on my opportunities. The feeling of being supported by an international mentor boosted my self-confidence and created a more brave and daring attitude toward future assignments. Conclusion: The mentorship program offered me a valuable opportunity in networking, goal reorientation, and career planning. I strongly advise young radiation oncology professionals, based on my personal experience, to participate in mentoring programs as it will make them rethink their own and institutional limits.

SP-0710 How to get involved in ESTRO leadership

A. Kirby 1

1 Royal Marsden/ Institute of Cancer Research, Radiotherapy, London, United Kingdom

Abstract Text This talk will begin with both objective and personal perspectives on the following questions: 1) What is ESTRO? 2) What is leadership? And 3) What does leadership in ESTRO look like? before describing, with examples, the routes through which you can become involved as a future leader within ESTRO.

Mini-Oral: 22: Mixed sites, palliation

MO-0711 Impact of operability and total metastatic ablation on outcomes after SABR for oligometastases

S. Siva 1 , M. Bressel 2 , P. Sogono 1 , M. Shaw 1 , S. Chander 1 , J. Chu 1 , N. Plumridge 1 , K. Byrne 1 , G. Kothari 1 , N. Bucknell 1 , N. Hardcastle 3 , T. Kron 3 , G. Wheeler 1 , M. MacManus 1 , G.G. Hanna 1 , D.L. Ball 1 , S. David 1 1 Peter MacCallum Cancer Centre, Department of Radiation Oncology, Melbourne, Australia; 2 Peter MacCallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Melbourne, Australia; 3 Peter MacCallum Cancer Centre, Department of Physical Sciences, Melbourne, Australia Purpose or Objective Operability status is prognostic for survival after SABR in primary non-small cell lung cancer. Subtotal ablation of all sites of oligometastases was negatively predictive of progression free survival (PFS) in the ORIOLE phase II trial. This study aims to assess the prognostic influence of operability and total metastatic ablation of all sites of oligometastatic disease. Materials and Methods Consecutive patients had operability status and presence of subtotal versus total metastatic ablation recorded prospectively on an institutional database. Data was retrospectively analysed with institutional ethical approval. Inclusion criteria was 1- 5 sites of active extracranial oligometastases. The primary objective was to compare overall survival (OS) and PFS between cohorts. Secondary objectives were to describe patterns of failure, high grade treatment toxicity (CTCAE v4.0), and freedom from systemic therapy (FFST). Multivariable Cox regression was performed to adjust for age, ECOG, Charlson Comorbidity Index (CCI), synchronous vs. metachronous oligometastases and number of metastasis at time of SABR. Results 401 patients with 530 treated oligometastases were included, with a median follow-up of 3 years. The median age was 67 years and 67% were male. Common histologies included prostate (24%), lung (18%), gastrointestinal (19%) and breast (11%). The total number of metastases (currently active and prior) was 1 in 47% of patients, 2-5 in 51%, and >5 in 2%. Radical treatment to the primary was delivered in 96% of patients. Grade 3-4 toxicities were reported in 3% (n=14). Cumulative incidence at 5-years of local only failure was 6%, local and distant was 2%, and distant only failure was 58%. The 3- and 5- year OS [95% CIs] were 68% [62-73] and 54% [47-61], and PFS was 20% [15-25] and 14% [10-20]. The 3- and 5-year FFST [95% CIs] was 40% [34-46] and 31% [24-37]. 76 patients were medically inoperable and 325 were medically operable. Inoperable patients were older (median 73 vs 65 years), had a higher CCI (median 10 vs 8) and poorer ECOG status (47% ECOG 0 vs 71%) than operable patients (all p-values <0.001). Operability status was not prognostic for OS (logrank p=0.095) or for PFS